Skip to content

PAM50 #
Find similar titles

The PAM50 test, designed to determine a risk of recurrence (ROR) score for patients with Breast cancer, adds significant prognostic information to clinical decision making and might be superior to other risk assays, findings from two recent studies indicate.

The assay is based on the PAM50 gene signature, which measures expression profiles for 50 genes and classifies tumors into four intrinsic subtypes

  • luminal A
  • luminal B
  • HER2-enriched
  • basal-like

An algorithm is then used to combine the gene signature, intrinsic subtype, tumor size, and proliferation score.

Incoming Links #

Related Medical Scholarly Articles #

Suggested Pages #